Literature DB >> 21464335

Tamoxifen regulation of bone growth and endocrine function in the ovariectomized rat: discrimination of responses involving estrogen receptor α/estrogen receptor β, G protein-coupled estrogen receptor, or estrogen-related receptor γ using fulvestrant (ICI 182780).

James M Fitts1, Robert M Klein, C Andrew Powers.   

Abstract

Tamoxifen is a selective estrogen receptor (ER) modulator, but it is also a deactivating ligand for estrogen-related receptor-γ (ERRγ) and a full agonist for the G protein-coupled estrogen receptor (GPER). Fulvestrant is a selective ER down-regulator that lacks agonist effects on ERα/ERβ, is inactive on ERRγ, but acts as a full agonist on GPER. Fulvestrant effects on tamoxifen actions on uterine and somatic growth, bone, the growth hormone (GH)-insulin-like growth factor I (IGF-I) axis, and pituitary prolactin were analyzed to pharmacologically discriminate tamoxifen effects that may be mediated by ERα/ERβ versus ERRγ versus GPER. Ovariectomized rats received tamoxifen (0.6 mg/kg/daily) plus fulvestrant at 0, 3, 6, or 12 mg/kg/daily for 5 weeks; controls received vehicle or 6 mg/kg fulvestrant daily. Tamoxifen effects to increase uterine weight, decrease serum IGF-I, increase pituitary prolactin, and increase bone mineral density could be fully blocked by fulvestrant, indicating mediation by ERα/ERβ. Tamoxifen effects to decrease pituitary GH, tibia length, and body weight were only partially blocked by fulvestrant, indicating involvement of mechanisms unrelated to ERα/ERβ. Fulvestrant did not inhibit tamoxifen actions to reduce total pituitary protein, again indicating effects not mediated by ERα/ERβ. Tamoxifen actions to reduce serum GH were mimicked rather than inhibited by fulvestrant, pharmacological features consistent with GPER involvement. However, fulvestrant alone increased IGF-I and also blocked tamoxifen-evoked IGF-I decreases; thus fulvestrant effects on serum GH might reflect increased IGF-I feedback inhibition. Fulvestrant alone had no effect on the other parameters. The findings indicate that mechanisms unrelated to ERα/ERβ contribute to tamoxifen effects on body weight, bone growth, and pituitary function.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21464335     DOI: 10.1124/jpet.110.173955

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

Review 1.  Minireview: Lymphangioleiomyomatosis (LAM): The "Other" Steroid-Sensitive Cancer.

Authors:  Hen Prizant; Stephen R Hammes
Journal:  Endocrinology       Date:  2016-07-13       Impact factor: 4.736

2.  Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors.

Authors:  George Notas; Vassiliki Pelekanou; Marilena Kampa; Konstantinos Alexakis; Stelios Sfakianakis; Aggelos Laliotis; John Askoxilakis; Eleftheria Tsentelierou; Maria Tzardi; Andreas Tsapis; Elias Castanas
Journal:  Mol Oncol       Date:  2015-06-05       Impact factor: 6.603

Review 3.  The G-protein-coupled estrogen receptor GPER in health and disease.

Authors:  Eric R Prossnitz; Matthias Barton
Journal:  Nat Rev Endocrinol       Date:  2011-08-16       Impact factor: 43.330

4.  Bisphenol A and its analogues disrupt centrosome cycle and microtubule dynamics in prostate cancer.

Authors:  Shuk-Mei Ho; Rahul Rao; Sarah To; Emma Schoch; Pheruza Tarapore
Journal:  Endocr Relat Cancer       Date:  2016-12-20       Impact factor: 5.678

5.  Influence of sex hormones and genetic predisposition in Sjögren's syndrome: a new clue to the immunopathogenesis of dry eye disease.

Authors:  Safinaz Mostafa; Vanessa Seamon; Ana Maria Azzarolo
Journal:  Exp Eye Res       Date:  2011-12-28       Impact factor: 3.467

6.  Tamoxifen Provides Structural and Functional Rescue in Murine Models of Photoreceptor Degeneration.

Authors:  Xu Wang; Lian Zhao; Yikui Zhang; Wenxin Ma; Shaimar R Gonzalez; Jianguo Fan; Friedrich Kretschmer; Tudor C Badea; Hao-Hua Qian; Wai T Wong
Journal:  J Neurosci       Date:  2017-02-24       Impact factor: 6.167

Review 7.  Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence.

Authors:  David F Archer; Bruce R Carr; JoAnn V Pinkerton; Hugh S Taylor; Ginger D Constantine
Journal:  Menopause       Date:  2015-07       Impact factor: 2.953

8.  A genome-wide association study of limb bone length using a Large White × Minzhu intercross population.

Authors:  Long-Chao Zhang; Na Li; Xin Liu; Jing Liang; Hua Yan; Ke-Bin Zhao; Lei Pu; Hui-Bi Shi; Yue-Bo Zhang; Li-Gang Wang; Li-Xian Wang
Journal:  Genet Sel Evol       Date:  2014-11-04       Impact factor: 4.297

9.  Mitochondrial estrogen receptors alter mitochondrial priming and response to endocrine therapy in breast cancer cells.

Authors:  Bahriye Karakas; Yeliz Aka; Asli Giray; Sehime Gulsun Temel; Ufuk Acikbas; Huveyda Basaga; Ozgur Gul; Ozgur Kutuk
Journal:  Cell Death Discov       Date:  2021-07-22

10.  Functional adaptation in female rats: the role of estrogen signaling.

Authors:  Susannah J Sample; Molly A Racette; Zhengling Hao; Cathy F Thomas; Mary Behan; Peter Muir
Journal:  PLoS One       Date:  2012-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.